{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:32:07Z","timestamp":1789129927724,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>During forced degradation, the intrinsic stability of active pharmaceutical ingredients (APIs) could be determined and possible impurities that would occur during the shelf life of the drug substance or the drug product could be estimated. Vildagliptin belongs to relatively new oral antidiabetic drugs named gliptins, inhibiting dipeptidyl peptidase 4 (DPP-4) and prolonging the activities of the endogenous incretin hormones. At the same time, some gliptins were shown as prone to degradation under specific pH and temperature conditions, as well as in the presence of some reactive excipients. Thus, forced degradation of vildagliptin was performed at high temperature in extreme pH and oxidative conditions. Then, selective LC-UV was used for quantitative determination of non-degraded vildagliptin in the presence of its degradation products and for degradation kinetics. Finally, identification of degradation products of vildagliptin was performed using an UHPLC-DAD-MS with positive ESI. Stability of vildagliptin was also examined in the presence of pharmaceutical excipients, using mid-IR and NIR with principal component analysis (PCA). At 70 \u00b0C almost complete disintegration of vildagliptin occurred in acidic, basic, and oxidative media. What is more, high degradation of vildagliptin following the pseudo first-order kinetics was observed at room temperature with calculated k values 4.76 \u00d7 10\u22124 s\u22121, 3.11 \u00d7 10\u22124 s\u22121, and 1.73 \u00d7 10\u22124 s\u22121 for oxidative, basic and acidic conditions, respectively. Next, new degradation products of vildagliptin were detected using UHPLC-DAD-MS and their molecular structures were proposed. Three degradants were formed under basic and acidic conditions, and were identified as [(3-hydroxytricyclo- [3.3.1.13,7]decan-1-yl)amino]acetic acid, 1-{[(3-hydroxytricyclo[3.3.1.13,7]decan-1-yl)amino]acetyl}-pyrrolidine-2-carboxylic acid and its O-methyl ester. The fourth degradant was formed in basic, acidic, and oxidative conditions, and was identified as 1-{[(3-hydroxytricyclo[3.3.1.13,7]-decan-1-yl)amino]acetyl}pyrrolidine-2-carboxamide. When stability of vildagliptin was examined in the presence of four excipients under high temperature and humidity, a visible impact of lactose, mannitol, magnesium stearate, and polyvinylpirrolidone was observed, affecting-NH- and CO groups of the drug. The obtained results (kinetic parameters, interactions with excipients) may serve pharmaceutical industry to prevent chemical changes in final pharmaceutical products containing vildagliptin. Other results (e.g., identification of new degradation products) may serve as a starting point for qualifying new degradants of vildagliptin as it is related to substances in pharmacopoeias.<\/jats:p>","DOI":"10.3390\/molecules26185632","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:13:47Z","timestamp":1631924027000},"page":"5632","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comprehensive Insight into Chemical Stability of Important Antidiabetic Drug Vildagliptin Using Chromatography (LC-UV and UHPLC-DAD-MS) and Spectroscopy (Mid-IR and NIR with PCA)"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-5272","authenticated-orcid":false,"given":"Anna","family":"Gumieniczek","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Berecka-Rycerz","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-0706","authenticated-orcid":false,"given":"Emilia","family":"Fornal","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-0018","authenticated-orcid":false,"given":"Barbara","family":"\u017by\u017cy\u0144ska-Granica","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-1321","authenticated-orcid":false,"given":"Sebastian","family":"Granica","sequence":"additional","affiliation":[{"name":"Microbiota Lab, Department of Pharmacognosy and Molecular Basis of Phytotherapy, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/1753-0407.12005","article-title":"Diabetes treatment: The coming paradigm shift","volume":"4","author":"Bloomgarden","year":"2012","journal-title":"J. Diabetes"},{"key":"ref_2","first-page":"229","article-title":"A review: Dipeptidylpeptidase-4 inhibitors (gliptins)","volume":"6","author":"Pate","year":"2017","journal-title":"World J. Pharm. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.2174\/0929867321666140915143309","article-title":"Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: A perspective","volume":"21","author":"Kushwaha","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_4","first-page":"113","article-title":"RP-HPLC determination of vildagliptin in pure and in tablet formulation","volume":"7","author":"Boovizhikannan","year":"2013","journal-title":"J. Pharm. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1134\/S1061934815040061","article-title":"Development and validation of reversed phase HPLC method for the determination of vildagliptin using an experimental design","volume":"70","author":"Kashid","year":"2015","journal-title":"J. Anal. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1556\/AChrom.27.2015.2.7","article-title":"Liquid chromatography tandem mass spectrometry (LC-MS\/MS) method for the determination of vildagliptin in rat plasma","volume":"27","author":"Sakthimanigandan","year":"2015","journal-title":"Acta Chromatogr."},{"key":"ref_7","first-page":"119","article-title":"Bioanalytical method development and validation of vildagliptin a novel dipeptidyl peptidase IV inhibitor by RP-HPLC method","volume":"4","author":"Pharne","year":"2012","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_8","first-page":"203","article-title":"HPLC-MS\/MS method for simultaneous quantification of vildagliptin, metformin, and metformin-related compounds in tablets","volume":"6","author":"Uber","year":"2014","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5530\/ijper.48.4.7","article-title":"Simultaneous determination of metformin and three gliptins in pharmaceutical formulations using RP HPLC: Application to stability studies on linagliptin tablet formulation","volume":"48","author":"Attimarad","year":"2014","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"ref_10","first-page":"128","article-title":"Simultaneous determination of metformin, sitagliptin, saxagliptin, linagliptin and vildagliptin in multicomponent pharmaceutical preparations by RP-HPLC","volume":"28","author":"Pednekar","year":"2014","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"ref_11","first-page":"361","article-title":"Determination of metformin and vildagliptin in solid dosage form and rabbit plasma by HPLC: An application to pharmacokinetic study","volume":"38","author":"Shakoor","year":"2019","journal-title":"Lat. Am. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10337-017-3288-0","article-title":"Development and validation of LC-MS\/MS method for simultaneous determination of metformin and four gliptins in human plasma","volume":"80","author":"Alhazmi","year":"2017","journal-title":"Chromatographia"},{"key":"ref_13","first-page":"388","article-title":"Bioanalytical method development and validation for simultaneous estimation of vildagliptin and enalapril maleate in rabbit plasma (K2 EDTA) using RP-HPLC","volume":"12","author":"Kishore","year":"2020","journal-title":"Int. J. Pharm. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5530\/jyp.2014.4.7","article-title":"Development of a rapid reversed phase-high performance liquid chromatography method for simultaneous determination of metformin and vildagliptin in formulation and human plasma","volume":"6","author":"Attimarad","year":"2014","journal-title":"J. Young Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/chromsci\/bms024","article-title":"Stability-indicating RP-LC method for the determination of vildagliptindagliptin and mass spectrometry detection for a main degradation product","volume":"50","author":"Barden","year":"2012","journal-title":"J. Chromatogr. Sci."},{"key":"ref_16","first-page":"124","article-title":"Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC","volume":"64","author":"Satheeshkumar","year":"2014","journal-title":"Drug Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.25004\/IJPSDR.2016.080306","article-title":"Development and validation of RP-HPLC assay method for vildagliptin using QbD approach and its application to forced degradation studies","volume":"8","author":"Chaphekar","year":"2016","journal-title":"Int. J. Pharm. Sci. Drug Res."},{"key":"ref_18","first-page":"129","article-title":"Stability testing of pharmaceutical products","volume":"2","author":"Bajaj","year":"2012","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trac.2006.05.011","article-title":"The importance and the challenges of impurity profiling in modern pharmaceutical analysis","volume":"25","year":"2006","journal-title":"TrAC trend Anal. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/10826076.2020.1779084","article-title":"New forced degradation products of vildagliptin: Identification and structural elucidation using LC-MS, with proposed formation mechanisms","volume":"43","author":"Arar","year":"2020","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpba.2015.11.044","article-title":"Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin","volume":"119","author":"Kumar","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/jssc.202100136","article-title":"Development and validation of an analytical method for quantitative determination of three potentially genotoxic impurities in vildagliptin drug material using HPLC-MS","volume":"44","author":"Harbali","year":"2021","journal-title":"J. Sep. Sci."},{"key":"ref_23","first-page":"20","article-title":"Managing excipient interactions","volume":"43","author":"Challener","year":"2019","journal-title":"PharmTech."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4236\/ajac.2016.71011","article-title":"Drug-excipient interactions: Case studies and overview of drug degradation pathways","volume":"7","author":"Hotha","year":"2016","journal-title":"Am. J. Anal. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jpba.2018.11.023","article-title":"Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods","volume":"164","author":"Gumieniczek","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_26","first-page":"69","article-title":"Formulation and evaluation of vildagliptin sustained release matrix tablets","volume":"6","author":"Sravani","year":"2014","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-hydroxy-1-adamantanyl)amino]acetyl]-2-cyjano-(S)-pyrrolidine; a potent, selective and orally available dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3109\/10837450.2011.591802","article-title":"and Chandragouda, R.P. Modification of pharmacological activity of nebivolol due to Maillard reaction","volume":"18","author":"Dipak","year":"2013","journal-title":"Pharm. Dev. Technol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/18\/5632\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:56Z","timestamp":1760166056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/18\/5632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":28,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["molecules26185632"],"URL":"https:\/\/doi.org\/10.3390\/molecules26185632","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}